Page 30 - pest-POSTEN nr 1, 2019

Cutterguide: No Printing Process: Offset
Size: 168x238 mm Pages: 2 Colors: C M Y K (4 Colors)
GD: RV32305
Native File: Indesign CS5 Windows Generated in: Acrobat Distiller XI
In the management of HIV,
TIMES ARE CHANGING

Are your treatment decisions changing with them?
We are introducing a 2-drug regimen for virologically suppressed adult HIV patients.

JULUCA (dolutegravir/rilpivirine) is indicated for the treatment of HIV-1 infection in adults
who are virologically suppressed (HIV-1 RNA <50 copies/ml) on a stable antiretroviral regimen
for at least six months with no history of virological failure and no known or suspected
resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.

Contraindications: proton pump inhibitors, dofetilide, rifampicin, rifapentine, carbamazepine,
oxcarbazepine, phenobarbital, phenytoin, systemic dexamethasone, St John’s wort.
Women of childbearing potential should undergo pregnancy testing before initiation of DTG
and use effective contraception throughout treatment. Due to the potential risk of neural
tube defects, DTG should not be used during the first trimester unless there is no alternative.

Les preparatomtale før forskrivning. Bivirkninger må rapporteres. Kontakt GSK på telefon 22 70 20 00.

JULUCA is owned by or licensed to the ViiV Healthcare group of companies.
©2019 ViiV Healthcare group of companies or its licensor. Mars 2019, PM-NO-DGR-JRNA-190001

LOC_NO JULUCA PRINT MAR 19 - 2DR-ad Update on PI text_D2.indd 1 3/4/2019 5:11:50 PM